Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
... Feb. 4, 2010 -- Four Oak Ridge National Laboratory ... five-year research grants as part of the Department of ... million program, funded under the American Recovery and Reinvestment ... to support exceptional researchers during the crucial early career ...
... , , IPSWICH, Mass. ... to the Wellcome Trust Sanger Institute, New England Biolabs is ... England Biolabs as one of its suppliers for next-generation sequencing ... "We are extremely pleased that the Wellcome Trust Sanger Institute, ...
Cached Biology Technology:New material absorbs, conserves oil 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing 2
(Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
(Date:9/30/2014)... A team of environmental scientists and engineers, led ... awarded a three-year, $5.25 million grant from the ... Competitive Research to make a direct positive impact ... remediation and disposal of radioactive contaminants. , "Understanding ... adequately dealing with environmental aspects of nuclear technologies ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
... The biggest ever single UK public investment in bioenergy ... main funding agency for the biosciences the Biotechnology ... 27M BBSRC Sustainable Bioenergy Centre has been launched to ... and emerging UK sustainable bioenergy sector and to ...
... Switzerland, Jan. 26 SVOX, the leading provider ... the Professional,Speech Processing Group of Siemens AG, according ... speech technology-related IP of Siemens AG developed,over 25 ... more than 60 patent families. The majority of ...
... Spring Harbor Laboratory (CSHL) announced today the discovery of ... time, they reported that their discovery suggests the presence ... in which these and possibly other small RNAs are ... project called ENCODE, also provided information concerning the biological ...
Cached Biology News:Biggest ever public investment in bioenergy to help provide clean, green and sustainable fuels 2SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2CSHL scientists find a new class of small RNAs and define its function 2CSHL scientists find a new class of small RNAs and define its function 3
Request Info...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Biology Products: